Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
|
Sonoma Pharmaceuticals, Inc. (SNOA)
|
Add to portfolio |
|
|
|
| Price: |
$4.80
| | Metrics |
| OS: |
3.1
|
M
| |
-82
|
% ROE
|
| Market cap: |
$14.9
|
M
| |
-63
|
% ROIC
|
|
Net cash:
|
$3.11
|
M
| |
$1.00
|
per share
|
|
EV:
|
$11.8
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($5.5)
|
M
| |
|
|
|
EBIT
|
($5.6)
|
M
| |
|
|
| EPS |
($2.03)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 | Mar-31-15 |
| Revenues | 12.6 | 18.6 | 17.9 | 19.0 | 16.7 | 12.8 | 9.4 | 13.9 |
| Revenue growth | -32.2% | 3.9% | -5.5% | 13.9% | 29.9% | 36.9% | -32.4% | 1.4% |
| Cost of goods sold | 9.4 | 12.1 | 9.8 | 10.1 | 9.3 | 7.2 | 6.7 | 6.6 |
| Gross profit | 3.2 | 6.6 | 8.1 | 8.9 | 7.3 | 5.7 | 2.6 | 7.3 |
| Gross margin | 25.5% | 35.2% | 45.3% | 46.8% | 43.9% | 44.2% | 28.3% | 52.6% |
| Selling, general and administrative | 9.8 | 9.5 | 14.2 | 18.6 | 19.9 | 17.1 | 15.6 | 12.4 |
| Research and development | 0.1 | 0.6 | 1.3 | 1.5 | 1.6 | 1.6 | 1.8 | 1.5 |
| EBIT | -5.9 | -3.4 | -7.4 | -11.3 | -14.2 | -13.0 | -14.7 | -6.7 |
| EBIT margin | -46.6% | -18.5% | -41.2% | -59.3% | -85.2% | -101.2% | -157.0% | -48.1% |
| Pre-tax income | -5.4 | -3.9 | -3.5 | -11.3 | -14.3 | -12.9 | -14.7 | -8.2 |
| Income taxes | -0.3 | 0.7 | 0.0 | 0.5 | 0.1 | -4.3 | 0.0 | 0.0 |
| Tax rate | 6.1% | | | | | 33.0% | 0.0% | 0.0% |
| Earnings from continuing ops | -5.1 | -5.3 | -3.6 | -11.8 | -14.3 | -26.6 | -19.3 | -8.2 |
| Earnings from discontinued ops | | 0.7 | 0.3 | | | 17.9 | 4.6 | |
| Net income | -5.1 | -4.6 | -3.3 | -11.8 | -14.3 | -8.7 | -14.7 | -8.2 |
| Net margin | -40.3% | -24.8% | -18.5% | -62.2% | -86.0% | -67.6% | -157.2% | -59.2% |
| |
| Diluted EPS | ($1.92) | ($2.65) | ($2.42) | ($12.77) | ($28.49) | ($6.30) | ($5.86) | ($0.85) |
| Shares outstanding (diluted) | 2.7 | 2.0 | 1.5 | 0.9 | 0.5 | 4.2 | 3.3 | 9.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|